The Discounted Cash Flow (DCF) valuation of Halozyme Therapeutics Inc (HALO) is 102.39 USD. With the latest stock price at 111.45 USD, the upside of Halozyme Therapeutics Inc based on DCF is -8.1%.
Based on the latest price of 111.45 USD and our DCF valuation, Halozyme Therapeutics Inc (HALO) is a sell. selling HALO stocks now will result in a potential gain of 8.1%.
| Range | Selected | |
| WACC / Discount Rate | 6.5% - 9.1% | 7.8% |
| Long-term Growth Rate | 2.5% - 4.5% | 3.5% |
| Fair Price | 62.59 - 234.94 | 102.39 |
| Upside | -43.8% - 110.8% | -8.1% |